-
Je něco špatně v tomto záznamu ?
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
TS. Tavares, J. Hofman, A. Lekešová, J. Želazková, V. Wsól,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
CZ.02.1.01/0.0/0.0/18_069/0010046
Ministerstvo Školství, Mládeže a Tělovýchovy
20-20414Y
Grantová Agentura České Republiky
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
33114555
DOI
10.3390/cancers12113127
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Olaparib is a potent poly (ADP-ribose) polymerase inhibitor currently used in targeted therapy for treating cancer cells with BRCA mutations. Here we investigate the possible interference of olaparib with daunorubicin (Daun) metabolism, mediated by carbonyl-reducing enzymes (CREs), which play a significant role in the resistance of cancer cells to anthracyclines. Incubation experiments with the most active recombinant CREs showed that olaparib is a potent inhibitor of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Subsequent inhibitory assays in the AKR1C3-overexpressing cellular model transfected human colorectal carcinoma HCT116 cells, demonstrating that olaparib significantly inhibits AKR1C3 at the intracellular level. Consequently, molecular docking studies have supported these findings and identified the possible molecular background of the interaction. Drug combination experiments in HCT116, human liver carcinoma HepG2, and leukemic KG1α cell lines showed that this observed interaction can be exploited for the synergistic enhancement of Daun's antiproliferative effect. Finally, we showed that olaparib had no significant effect on the mRNA expression of AKR1C3 in HepG2 and KG1α cells. In conclusion, our data demonstrate that olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21001897
- 003
- CZ-PrNML
- 005
- 20210126092726.0
- 007
- ta
- 008
- 210105s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers12113127 $2 doi
- 035 __
- $a (PubMed)33114555
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Tavares, Tássia S $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 245 10
- $a Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. / $c TS. Tavares, J. Hofman, A. Lekešová, J. Želazková, V. Wsól,
- 520 9_
- $a Olaparib is a potent poly (ADP-ribose) polymerase inhibitor currently used in targeted therapy for treating cancer cells with BRCA mutations. Here we investigate the possible interference of olaparib with daunorubicin (Daun) metabolism, mediated by carbonyl-reducing enzymes (CREs), which play a significant role in the resistance of cancer cells to anthracyclines. Incubation experiments with the most active recombinant CREs showed that olaparib is a potent inhibitor of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Subsequent inhibitory assays in the AKR1C3-overexpressing cellular model transfected human colorectal carcinoma HCT116 cells, demonstrating that olaparib significantly inhibits AKR1C3 at the intracellular level. Consequently, molecular docking studies have supported these findings and identified the possible molecular background of the interaction. Drug combination experiments in HCT116, human liver carcinoma HepG2, and leukemic KG1α cell lines showed that this observed interaction can be exploited for the synergistic enhancement of Daun's antiproliferative effect. Finally, we showed that olaparib had no significant effect on the mRNA expression of AKR1C3 in HepG2 and KG1α cells. In conclusion, our data demonstrate that olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Lekešová, Alžběta $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Želazková, Jana $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Wsól, Vladimír $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 11 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33114555 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210126092722 $b ABA008
- 999 __
- $a ind $b bmc $g 1614060 $s 1122181
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 12 $c 11 $e 20201026 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a CZ.02.1.01/0.0/0.0/18_069/0010046 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a 20-20414Y $p Grantová Agentura České Republiky
- LZP __
- $a Pubmed-20210105